PDCD1 and mesothelioma: Combination therapies involving a PD-1 inhibitor and a CTLA-4 inhibitor or kinase-targeting therapies are gaining traction as viable strategies to treat mesothelioma, so much so that one of the combinations was approved for clinical use as a first-line therapy.